SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* GRASMICK LOUIS J (Last) (First) (Middle) C/O CAPRICOR THERAPEUTICS, INC. 8840 WILSHIRE BLVD., 2ND FLOOR (Street) BEVERLY HILLS CA 90211 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 11/20/2013	3. Issuer Name and Ticker or Trading Symbol CAPRICOR THERAPEUTICS, INC. [ NLTXD ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
COMMON STOCK	897,512	I	See Footnote(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	11/01/2007(2)	11/01/2017	COMMON STOCK	20,748	0.16	D
Stock Option (right to buy)	09/25/2010(3)	09/25/2020	COMMON STOCK	82,994	0.37	D
Stock Option (right to buy)	04/27/2012(4)	04/27/2022	COMMON STOCK	154,555	0.37	D
Stock Option (right to buy)	04/27/2012(5)	04/27/2022	COMMON STOCK	124,491	0.37	D
Stock Option (right to buy)	02/22/2013(6)	02/22/2023	COMMON STOCK	14,015	0.37	D

Explanation of Responses:

1. 897,512 shares of common stock are beneficially owned by Nancelou, Inc. Mr. Grasmick and his wife each own 50% of Nancelou, Inc. and therefore are deemed to be the beneficial owners of all shares of Capricor Therapeutics, Inc. held by Nancelou, Inc. Mr. Grasmick and his wife are deemed to have shared voting and dispositive power with respect to the shares beneficially owned by Nancelou, Inc.

2. Vesting schedule is as follows: This option is deemed fully vested.

3. Vesting schedule is as follows: This option is deemed fully vested.

4. Vesting schedule is as follows: This option vests monthly over 48 months commencing May 1, 2012.

5. Vesting schedule is as follows: This option is deemed fully vested.

6. Vesting schedule is as follows: 25% of the shares of common stock subject to this option vested immediately, with the remainder vesting over 36 months commencing May 1, 2013.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Linda Marban, as Attorney-in-Fact	11/30/2013
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.